MIRA Pharmaceuticals, Inc. Net Change in Cash
MIRA Pharmaceuticals, Inc. (MIRA) reported Net Change in Cash of -$2.74 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-12
- MIRA Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$1.53M.
- MIRA Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$1.63M.
- MIRA Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$1.07M.
- MIRA Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$349.63K.
- MIRA Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $3.51M.
- MIRA Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$1.77M, a 141.62% decline from fiscal 2023.
- MIRA Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $4.25M.
- MIRA Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$2.46M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.74M 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | -$1.53M 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $3.51M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | -$191.39K 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | -$2.10M 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | -$1.63M 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | -$1.77M 10-K · filed 2026-03-31 | |||
| 2024-09-30 | -$458.01K 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | -$1.78M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | -$1.07M 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $4.25M 10-K · filed 2025-03-28 | |||
| 2023-09-30 | $5.52M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | -$326.15K 10-Q/A · filed 2024-08-16 | |||
| 2023-03-31 | -$349.63K 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | -$2.46M 10-K · filed 2024-04-01 | |||
| 2022-09-30 | -$2.62M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | -$1.98M 10-Q · filed 2023-09-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |